
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.8 | 1.25 | 1.34 | 1.1901 | 157430 | 1.26059336 | CS |
4 | -0.06 | -4.61538461538 | 1.3 | 1.44 | 1.14 | 193145 | 1.2951998 | CS |
12 | 0.02 | 1.6393442623 | 1.22 | 1.53 | 0.73 | 1270567 | 1.09470716 | CS |
26 | 0.17 | 15.8878504673 | 1.07 | 1.53 | 0.73 | 796530 | 1.11388809 | CS |
52 | 0.528 | 74.1573033708 | 0.712 | 5.01 | 0.51 | 2178657 | 2.70378924 | CS |
156 | -5.76 | -82.2857142857 | 7 | 7.9799 | 0.51 | 1309104 | 2.62410092 | CS |
260 | -5.76 | -82.2857142857 | 7 | 7.9799 | 0.51 | 1309104 | 2.62410092 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions